• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Gall Matthew

    11/3/25 5:23:04 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLRS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Gall Matthew

    (Last) (First) (Middle)
    C/O KALARIS THERAPEUTICS, INC.
    400 CONNELL DRIVE SUITE 5500

    (Street)
    BERKELEY HEIGHTS NJ 07922

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/03/2025
    3. Issuer Name and Ticker or Trading Symbol
    Kalaris Therapeutics, Inc. [ KLRS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ Matthew Gall 11/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KLRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLRS

    DatePrice TargetRatingAnalyst
    12/23/2025$19.00Buy
    Chardan Capital Markets
    11/3/2025$20.00Mkt Outperform
    Citizens JMP
    9/3/2025$23.00Strong Buy
    Raymond James
    7/23/2025$3.00Neutral
    Piper Sandler
    5/7/2025$20.00Outperform
    Leerink Partners
    4/8/2025Outperform
    William Blair
    More analyst ratings

    $KLRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas was granted 1,500,000 shares (SEC Form 4)

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    12/22/25 4:15:40 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Gall Matthew

    4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    11/3/25 5:25:05 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Gall Matthew

    3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

    11/3/25 5:23:04 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.

    SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)

    12/22/25 4:17:04 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

    12/18/25 7:29:17 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

    12/17/25 5:19:38 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $KLRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

    BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a

    1/28/26 4:05:00 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

    BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses. The private placement includes participation from both new and existing investors, including ADAR1 Capital Management, Coastlands Capital, Invus

    12/17/25 5:59:02 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

    TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c

    12/17/25 4:01:00 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets initiated coverage on Kalaris Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00

    12/23/25 8:43:15 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Kalaris Therapeutics with a new price target

    Citizens JMP initiated coverage of Kalaris Therapeutics with a rating of Mkt Outperform and set a new price target of $20.00

    11/3/25 9:08:29 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on Kalaris Therapeutics with a new price target

    Raymond James initiated coverage of Kalaris Therapeutics with a rating of Strong Buy and set a new price target of $23.00

    9/3/25 8:38:32 AM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLRS
    Financials

    Live finance-specific insights

    View All

    Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

    TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c

    12/17/25 4:01:00 PM ET
    $KLRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care